| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 42,810 | 25,900 | 31,420 | 29,320 | 46,280 |
| Sales Growth | +65.29% | -17.57% | +7.16% | -36.65% | +59.04% |
| Net Income | -24,540 | -33,280 | -45,740 | -37,230 | -25,470 |
| Net Income Growth | +26.26% | +27.24% | -22.86% | -46.17% | +4.79% |
Palvella Therapeutics Inc (PVLA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
27.43 -0.18 (-0.65%) 03/20/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 27.43 unch (unch) 16:00 ET
for Thu, Mar 20th, 2025
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Fiscal Year End Date: 12/31